Virology & Mycology
ISSN: 2161-0517
OPEN ACCESS Freely available online
Short Communication

# Fungal and Viral Co-Infections in Immunocompromised Hosts

**Thandiwe Mokoena***

*Division of Clinical Infectious Diseases, University of Cape Town, Cape Town, Western Cape, South Africa*

## DESCRIPTION

Fungal and viral co-infections represent a significant and growing concern in the management of immunocompromised patients. Individuals undergoing chemotherapy, organ transplantation, or immunosuppressive therapies for autoimmune conditions, as well as those with HIV/AIDS, are particularly vulnerable to opportunistic infections. These infections often do not occur in isolation but rather in tandem, with viral and fungal pathogens exploiting compromised immune defenses to establish persistent, invasive diseases. The interaction between these pathogens exacerbates disease severity, complicates treatment regimens, and contributes to high morbidity and mortality, especially in healthcare settings where delayed diagnosis and limited antifungal or antiviral options may hinder timely intervention.

In immunocompromised hosts, viral infections such as cytomegalovirus (CMV), Epstein-Barr Virus (EBV), and Herpes Simplex Virus (HSV) often act as gatekeepers, weakening mucosal and immune barriers and allowing secondary fungal infections to take hold. CMV, for instance, has been closely associated with the onset of invasive fungal infections in post-transplant patients, particularly Candida and Aspergillus species, by suppressing neutrophil and T-cell function [1]. Similarly, HSV-induced mucosal damage can facilitate fungal colonization in the oral and esophageal regions. The emergence of COVID-19 has further heightened attention to such coinfections, as cases of COVID-19-associated pulmonary aspergillosis (CAPA) and mucormycosis have been widely documented, especially in patients receiving corticosteroids [2,3].

Fungal pathogens in these co-infections are notoriously difficult to treat due to delayed diagnosis, limited antifungal penetration into infected tissues, and intrinsic or acquired resistance mechanisms. Candida auris, an emerging multidrug-resistant fungus, has been frequently identified in patients co-infected with viral pathogens in intensive care units, raising alarms due to its high mortality and transmission potential [4]. Meanwhile, invasive Aspergillus infections in the lungs are often misdiagnosed as viral pneumonia or bacterial infections, delaying the initiation of appropriate antifungal therapy. Such diagnostic ambiguity is especially dangerous in viral-fungal co-infections, where early intervention can be life-saving.

From an immunological perspective, viral and fungal pathogens manipulate host defenses in distinct but often synergistic ways. Viruses like HIV deplete CD4+ T-cells, which are essential for antifungal immunity, whereas fungal infections, in turn, may induce immunosuppressive cytokines such as IL-10, further blunting antiviral responses [5]. Moreover, viral replication can increase host cell apoptosis and disrupt epithelial barriers, creating niches for fungal spores to adhere and invade. These synergistic effects contribute to the chronicity of infections, higher pathogen load, and increased tissue damage.

In resource-constrained settings such as parts of sub-Saharan Africa, where both HIV prevalence and healthcare infrastructure limitations co-exist, fungal-viral co-infections are even more perilous. Limited diagnostic tools mean that many cases go unrecognized until severe complications arise. Furthermore, antifungal medications like amphotericin B and voriconazole may not be readily available or affordable, restricting treatment options and contributing to high fatality rates [6,7]. Despite these challenges, clinical awareness is gradually increasing, and efforts are underway to integrate fungal diagnostics into existing viral disease programs, particularly in HIV care [8].

Advances in diagnostic methodologies such as multiplex PCR panels, next-generation sequencing (NGS), and fungal antigen assays (e.g., galactomannan, β-D-glucan) offer promise for the early and accurate detection of co-infections [9]. However, these tools are still underutilized in many healthcare systems due to cost and logistical barriers. In the meantime, clinical suspicion and empirical treatment based on risk stratification remain the cornerstones of managing suspected cases of viral-fungal co-infection.

Prophylactic strategies are also evolving. In transplant patients, for example, the use of prophylactic antivirals (e.g., valganciclovir) and antifungals (e.g., posaconazole) has been shown to reduce the incidence of co-infections when used in a targeted manner based on risk profiles [10]. Importantly, individualized care plans that consider the patient's immuno-

**Correspondence to:** Division of Clinical Infectious Diseases, University of Cape Town, Cape Town, Western Cape, South Africa, E-mail: thandiwe.mokoena.id@uctza.ac.za

**Received:** 03-Mar-2025, Manuscript No. VMID-25-37642; **Editor assigned:** 06-Mar-2025, PreQC No. VMID-25-37642 (PQ); **Reviewed:** 20-Mar-2025, QC No. VMID-25-37642; **Revised:** 27-Mar-2025, Manuscript No. VMID-25-37642 (R); **Published:** 03-Apr-2025. DOI: 10.35248/2161-0517.25.14.318

**Citation:** Mokoena T (2025). Fungal and Viral Co-Infections in Immunocompromised Hosts. Virol Myco.14:318.

logical status, underlying disease, and treatment history are vital for achieving optimal outcomes.

## CONCLUSION

Fungal and viral co-infections in immunocompromised hosts pose a multifaceted clinical challenge marked by complex pathogen interactions, diagnostic delays, and limited treatment options. As these infections become increasingly prevalent, especially in the wake of global viral outbreaks and expanding use of immunosuppressive therapies, there is a pressing need to improve diagnostic capacity, develop combination treatment protocols, and strengthen surveillance systems. In South Africa and other similar contexts, investments in infectious disease training, laboratory infrastructure, and access to advanced therapies will be essential to reduce the burden of these lethal co-infections and improve patient outcomes.

## REFERENCES

1. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711–5719.
2. Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: We should be prepared. J Mycol Med. 2020;30:100971.
3. Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: A clinical and diagnostic perspective. Mycopathologia. 2020;185:599–606.
4. Chowdhary A, Sharma C, Meis JF. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017;13:e1006290.
5. Lionakis MS, Netea MG, Holland SM. Mendelian genetics of human fungal infections. Cell Host Microbe. 2014;15:433–445.
6. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases-Estimate precision. J Fungi. 2017;3:57.
7. Rajasingham R, Smith RM, Park BJ. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17:873–881.
8. Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18:e339–e347.
9. Clancy CJ, Nguyen MH. Diagnosing invasive candidiasis. J Clin Microbiol. 2018;56:e01909-17. [Crossref][Google Scholar] [PubMed]
10. Kern WV. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis. 2006 Feb 15;42:533-40.